PT  - JOURNAL ARTICLE
AU  - Thilagar, Bright P.
AU  - Ghosh, Aditya K.
AU  - Nguyen, Jerome
AU  - Theiler, Regan N.
AU  - Wick, Myra J.
AU  - Hurt, Ryan T.
AU  - Razonable, Raymund R.
AU  - Ganesh, Ravindra
TI  - Outcomes of Anti-Spike Monoclonal Antibody Therapy in Pregnant Women with Mild to Moderate COVID-19
AID  - 10.1101/2021.11.27.21266942
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.11.27.21266942
4099  - http://medrxiv.org/content/early/2021/11/28/2021.11.27.21266942.short
4100  - http://medrxiv.org/content/early/2021/11/28/2021.11.27.21266942.full
AB  - Objective To evaluate the efficacy and safety of anti-spike monoclonal antibodies (MAb) in the treatment of mild to moderate COVID-19 in high-risk patients who are pregnant.Methods The database of patients treated with monoclonal antibodies in the Mayo Clinic Midwest region was reviewed for patients who were pregnant at the time of infusion. Manual chart review was performed to collect demographic details as well as COVID course for both the mother and the infant if delivered. The data are presented using descriptive methods.Results We identified fifty-one pregnant patients with mild to moderate COVID-19 who were treated with MAb (4 with bamlanivimab monotherapy, 3 with bamlanivimab-etesevimab combination, and 44 with the casirivimab-imdevimab combination). No adverse effects were reported, and no patient required COVID-19 related hospitalization. Twenty-nine patients delivered healthy babies, there was one case of intrauterine fetal demise secondary to a congenital Ebstein anomaly (not related to MAb treatment), and twenty-one were uncomplicated pregnancies.Conclusion MAb infusions were well tolerated in pregnant patients considered at high risk for COVID-19 complications, with no observed adverse effects to mother or fetus. Although preliminary data suggest MAb therapy in pregnancy is safe, further research is recommended to fully assess safety and efficacy in pregnancy.TEACHING POINTSAnti-spike monoclonal antibody therapy is well tolerated in high-risk pregnant patients with mild to moderate COVID-19No adverse effects of anti-spike monoclonal antibody administration were observed in either the mother or fetus.Competing Interest StatementAKG, JN, RNT, MJW, BPT, and RG have no financial disclosures. RRR is principal investigator of clinical trials on COVID-19 treatment funded by Gilead (remdesivir), Regeneron (sarilumab, casirivimab-imdevimab), Roche (tocilizumab), and research on Monoclonal Antibody Therapy funded by the Mayo Clinic. RTH is a consultant for Nestle NutritionFunding StatementThis study was funded by the Mayo ClinicAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Mayo Clinic IRB gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors